Published in Oncogene on October 12, 2015
Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations. Oncotarget (2017) 0.97
Recurrent SRF-RELA Fusions Define a Novel Subset of Cellular Myofibroma/Myopericytoma: A Potential Diagnostic Pitfall With Sarcomas With Myogenic Differentiation. Am J Surg Pathol (2017) 0.81
PDGF-induced fibroblast growth requires monounsaturated fatty acid production by stearoyl-CoA desaturase. FEBS Open Bio (2017) 0.75
Unwanted acquired mutations in Ba/F3 transformation assays. Oncotarget (2017) 0.75
Case report: rapid and durable response to PDGFR targeted therapy in a child with refractory multiple infantile myofibromatosis and a heterozygous germline mutation of the PDGFRB gene. BMC Cancer (2017) 0.75
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Role of platelet-derived growth factors in physiology and medicine. Genes Dev (2008) 8.89
A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med (2011) 8.26
Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev (1994) 5.04
Signal transduction via platelet-derived growth factor receptors. Biochim Biophys Acta (1998) 3.86
The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development (1997) 3.78
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol (2005) 3.73
Infantile myofibromatosis. Cancer (1981) 2.55
Mutation of the PDGFRB gene as a cause of idiopathic basal ganglia calcification. Neurology (2012) 2.05
Phenotypic spectrum of probable and genetically-confirmed idiopathic basal ganglia calcification. Brain (2013) 2.02
PDGF receptor signaling networks in normal and cancer cells. Cytokine Growth Factor Rev (2014) 1.85
A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet (2013) 1.66
Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis. Am J Hum Genet (2013) 1.63
A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology (1998) 1.52
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood (2006) 1.47
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood (2010) 1.18
STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells. Cancer Res (2000) 1.14
Activating ALK mutations found in neuroblastoma are inhibited by Crizotinib and NVP-TAE684. Biochem J (2011) 1.11
Infantile myofibromatosis. Pediatrics (1985) 1.04
Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase by its C-terminal tail. J Biol Chem (2004) 1.03
PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations. Oncogene (2013) 1.00
Extracellular assembly and activation principles of oncogenic class III receptor tyrosine kinases. Nat Rev Cancer (2012) 0.99
Autosomal dominant inheritance of infantile myofibromatosis. Am J Med Genet A (2004) 0.96
A gain of function mutation in the activation loop of platelet-derived growth factor beta-receptor deregulates its kinase activity. J Biol Chem (2004) 0.91
KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia (2010) 0.91
Idiopathic basal ganglia calcification-associated PDGFRB mutations impair the receptor signalling. J Cell Mol Med (2014) 0.89
Overgrowth syndromes: is dysfunctional PI3-kinase signalling a unifying mechanism? Eur J Hum Genet (2003) 0.85
Novel overgrowth syndrome phenotype due to recurrent de novo PDGFRB mutation. J Pediatr (2014) 0.85
The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1-PDGFRα and PDGFRα D842V. Mol Oncol (2014) 0.85
Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK. Haematologica (2011) 0.84
MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene (2003) 0.83
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia. Eur J Cancer (2014) 0.82
Infantile myofibromatosis: a case report and review of the literature. Cutis (2004) 0.82
Platelet-derived growth factor receptor inducibility is acquired immediately after translation and does not require glycosylation. J Biol Chem (1989) 0.82
Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. Eur J Clin Pharmacol (2010) 0.81
Differential diagnoses of overgrowth syndromes: the most important clinical and radiological disease manifestations. Radiol Res Pract (2014) 0.80
Infantile myofibromatosis: a series of 28 cases. J Am Acad Dermatol (2014) 0.80
Familial occurrence of infantile myofibromatosis. Cancer (1992) 0.79
An activating mutation in the PDGF receptor-beta causes abnormal morphology in the mouse placenta. Int J Dev Biol (2007) 0.78
Modulation of expressivity in PDGFRB-related infantile myofibromatosis: a role for PTPRG? Genet Mol Res (2014) 0.77